January 23, 2021

U.S. secures 300 million doses of potential AstraZeneca COVID-19 vaccine

The United States has secured almost a third of AstraZeneca’s one billion possible COVID-19 vaccine doses by pledging up to $1.2 billion, as the world’s biggest powers scramble for medicinal supplies to get their economies back to work.

While not proven to be effective against the coronavirus, vaccines are seen by world leaders as the only real way to restart their stalled economies, and even to get an edge over global competitors.

After President Donald Trump demanded a vaccine, the U.S. Department of Health agreed to provide up to $1.2 billion to accelerate AstraZeneca’s vaccine development and secure 300 million doses for the United States.

“This contract with AstraZeneca is a major milestone in Operation Warp Speed’s work toward a safe, effective, widely available vaccine by 2021,” U.S. Health Secretary Alex Azar said.

The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to British drugmaker AstraZeneca. Immunity to the new coronavirus is uncertain and so the use of vaccines unclear.

The U.S. deal allows a late-stage – Phase III – clinical trial of the vaccine with 30,000 people in the United States.

AstraZeneca, based in Cambridge, England, said it had concluded agreements for at least 400 million doses of the vaccine and secured manufacturing capacity for one billion doses, with first deliveries due to begin in September.

Now the most valuable company on Britain’s blue-chip FTSE 100 Index, it has already agreed to deliver 100 million doses to people in Britain, with 30 million as soon as September. Ministers have promised that Britain will get first access to the vaccine.

Leave a Reply

Your email address will not be published. Required fields are marked *